Public Science, Private Checkout
I keep a library card and a calculator nearby for moments like this: taxpayers help fund NIH and university research, then meet the finished medicine at the pharmacy counter priced like a used county courthouse. Not every treatment follows that exact route, and public research can benefit everyone. But when public money absorbs much of the early risk while private companies control the patent and the price, the arrangement deserves more than a ceremonial ribbon cutting.
The institutional math is remarkably tidy. Public laboratories supply knowledge, universities supply talent, investors celebrate the next big product, and patients receive the portion marked “due now.” That is not necessarily unlawful; it is simply a system with impressive machinery for privatizing the upside and outsourcing the bill. A sensible public investment should purchase public leverage, affordable access, or both. Otherwise taxpayers sponsored discovery, investors collected the dividend, and patients were assigned to crowd-fund the receipt.